Tonix Pharmaceuticals Has Completed The Clinical Phase Of The Phase 2 Proof-Of-Concept PREVAIL Study Of TNX-102 SL As A Potential Treatment For Fibromyalgia-Type Long Covid. Topline Results Are Expected In Q3 Of 2023
Portfolio Pulse from Benzinga Newsdesk
Tonix Pharmaceuticals has completed the clinical phase of the Phase 2 proof-of-concept PREVAIL study of TNX-102 SL, a potential treatment for fibromyalgia-type long Covid. The topline results are expected to be released in Q3 of 2023.
August 07, 2023 | 11:24 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Tonix Pharmaceuticals' completion of the clinical phase of the Phase 2 study for TNX-102 SL could potentially impact the company's stock positively, pending the results in Q3 2023.
The completion of the clinical phase of a study is a significant milestone for pharmaceutical companies. This news could potentially increase investor confidence in Tonix Pharmaceuticals, leading to a positive impact on the company's stock. However, the actual impact will largely depend on the results of the study, which are expected in Q3 2023.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100